| Legal Status: | Investigational |
| Iupac Name: | N-Hydroxy-5-methylfuran-2-sulfonamide |
| Cas Number: | 1620330-72-4 |
| Pubchem: | 76685198 |
| Drugbank: | DB14983 |
| Unii: | 2US4FK1EPV |
| C: | 5 |
| H: | 7 |
| N: | 1 |
| O: | 4 |
| S: | 1 |
| Smiles: | CC1=CC=C(O1)S(=O)(=O)NO |
Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a precursor of nitroxyl.[1]
Cimlanod is a prodrug of CXL-1020.[2]
A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.